Inventor
MEYERSON MATTHEW
US30 patents
⚠️ This page may combine multiple inventors who share the name “MEYERSON MATTHEW”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BROAD INST INC
9 patentsUS11142522B2Oct 12, 2021
Compounds, compositions and methods for cancer treatment
BROAD INST INC4 citations72
US9890127B2Feb 13, 2018
Compounds and compositions for the treatment of cancer
BROAD INST INC3 citations67
US11207320B2Dec 28, 2021
Compositions and methods for cancer expressing PDE3A or SLFN12
BROAD INST INC0 citations59
US11896678B2Feb 13, 2024
Compositions and methods for treatment of peroxisome proliferator-activated receptor gamma (PPARG) activated cancer
BROAD INST INC0 citations56
US10449199B2Oct 22, 2019
Compositions and methods for sensitizing a neoplastic cell to radiation
BROAD INST INC0 citations49
US9439909B2Sep 13, 2016
Compositions and methods for sensitizing a neoplastic cell to radiation
BROAD INST INC0 citations49
US10385403B2Aug 20, 2019
DDR2 mutations in squamous cell lung cancer
BROAD INST INC0 citations44
US9499856B2Nov 22, 2016
DDR2 mutations in squamous cell lung cancer
BROAD INST INC0 citations44
US10590473B2Mar 17, 2020
Rapid quantitative detection of single nucleotide polymorphisms or somatic variants and methods to identify malignant neoplasms
BROAD INST INC0 citations28
DANA FARBER CANCER INST INC
6 patentsUS11946105B2Apr 2, 2024
Bacterial etiology of colorectal cancer
DANA FARBER CANCER INST INC0 citations55
US11060148B2Jul 13, 2021
Diagnosing and treating colorectal cancer
DANA FARBER CANCER INST INC1 citations55
US12239646B2Mar 4, 2025
Cancer diagnostic and treatment
DANA FARBER CANCER INST INC0 citations53
US11873486B2Jan 16, 2024
Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
DANA FARBER CANCER INST INC0 citations53
US11926874B2Mar 12, 2024
Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms
DANA FARBER CANCER INST INC0 citations51
US10723753B2Jul 28, 2020
Ras inhibitors and uses thereof
DANA FARBER CANCER INST INC0 citations38
BAYER AG
5 patentsUS11773070B2Oct 3, 2023
Dihydrooxadiazinones
BAYER AG2 citations72
US11427553B2Aug 30, 2022
Dihydrooxadiazinones
BAYER AG4 citations72
US11339157B1May 24, 2022
4H-pyrrolo[3,2-c]pyridin-4-one derivatives
BAYER AG2 citations69
US12258323B2Mar 25, 2025
Dihydrooxadiazinones
BAYER AG1 citations63
US12403135B2Sep 2, 2025
4H-pyrrolo[3,2-c]pyridin-4-one derivatives
BAYER AG0 citations47
GEN HOSPITAL CORP
3 patentsUS7964349B2Jun 21, 2011
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
GEN HOSPITAL CORP92 citations98
US7294468B2Nov 13, 2007
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
GEN HOSPITAL CORP187 citations98
US9035036B2May 19, 2015
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
GEN HOSPITAL CORP8 citations83
MASSACHUSETTS GEN HOSPITAL
3 patentsUS12006555B2Jun 11, 2024
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
MASSACHUSETTS GEN HOSPITAL0 citations62
US10669589B2Jun 2, 2020
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
MASSACHUSETTS GEN HOSPITAL0 citations51
US10000815B2Jun 19, 2018
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
MASSACHUSETTS GEN HOSPITAL0 citations51
BELL DAPHNE WINIFRED
2 patentsUS8465916B2Jun 18, 2013
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
BELL DAPHNE WINIFRED85 citations97
US8105769B2Jan 31, 2012
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
BELL DAPHNE WINIFRED97 citations96